- Home
- KRC vs NAMS Comparison
KRC vs NAMS Comparison
Compare KRC & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KRC | NAMS |
|---|---|---|
| Founded | 1947 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | 100 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 4.1B |
| IPO Year | 1996 | N/A |
Fundamental Metrics
Financial Performance| Metric | KRC | NAMS |
|---|---|---|
| Price | $38.49 | $35.16 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 8 |
| Target Price | $37.36 | ★ $46.75 |
| AVG Volume (30 Days) | ★ 1.4M | 1.1M |
| Earning Date | 04-27-2026 | 05-06-2026 |
| Dividend Yield | ★ 6.57% | N/A |
| EPS Growth | ★ 31.07 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,112,667,000.00 | N/A |
| Revenue This Year | N/A | $17.96 |
| Revenue Next Year | $2.13 | $540.65 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $27.36 | $20.53 |
| 52 Week High | $45.03 | $42.21 |
Technical Indicators
Market Signals| Indicator | KRC | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 57.61 | 57.72 |
| Support Level | $37.07 | $33.83 |
| Resistance Level | $39.85 | $37.27 |
| Average True Range (ATR) | 0.88 | 1.74 |
| MACD | -0.10 | 0.42 |
| Stochastic Oscillator | 59.94 | 71.19 |
Price Performance
Historical ComparisonAbout KRC Kilroy Realty Corporation
Kilroy Realty is a premier owner and landlord of approximately 16.3 million square feet of office space across Los Angeles, San Diego, the San Francisco Bay Area, Austin, Texas, and greater Seattle. The company operates as a real estate investment trust.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.